The Online Investor
Diagnostics M&A image Diagnostics M&A » By The Online Investor Staff, updated Sat., Feb. 29, 1:42 AM Recent mergers and acquisitions in the Diagnostics M&A category.

Slide #69. BioScrip CarePoint Partners Home Infusion Business

Acquirer: BioScrip (BIOS)
Acquiree: CarePoint Partners Home Infusion Business
Details: BioScrip, Inc. (NASDAQ: BIOS) today announced that it has entered into a definitive agreement to acquire the business of CarePoint Partners Holdings LLC and its subsidiaries (collectively, "CarePoint Partners") for $223 million in cash, subject to certain adjustments. CarePoint Partners is a leading national provider of home and alternate-site infusion therapy for patients with complex, acute and chronic illnesses. BioScrip also expects to realize the value of a future tax benefit estimated at $45 million as a result of the transaction, yielding a net purchase price of $178 million.

Option Care Health is a provider of infusion and home care management solutions. Co. partners with physicians, hospital systems, payors, pharmaceutical manufacturers and nursing facilities to provide patients access to post-acute care services. Whether in the home, physician office, ambulatory infusion center, nursing facility or other alternate sites of care, Co. provides products, services and condition-specific clinical management programs tailored to improve the care of individuals with health conditions such as gastrointestinal abnormalities, infectious diseases, cancer, multiple sclerosis, organ and blood cell transplants, bleeding disorders, immune deficiencies and heart failure.

Open the BIOS Page at The Online Investor »

Company Name: 
Option Care Health Inc
Website: 
www.bioscrip.com
Sector: 
Diagnostics
Number of ETFs Holding BIOS: 
1
Total Market Value Held by ETFs: 
$267134
Total Market Capitalization: 
$3.07B
% of Market Cap. Held by ETFs: 
0.01%
 

Open the BIOS Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Diagnostics M&A - Slide 69 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.